Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)Naoya Yamazaki, Kenji Yokota, Yoshio Kiyohara et al.|Cancer Chemotherapy and Pharmacology|2017Cited by 89
First‐line pembrolizumab vs chemotherapy in metastatic non‐small‐cell lung cancer: KEYNOTE‐024 Japan subset*Miyako Satouchi, Katsuyuki Hotta, Kaname Nosaki et al.|Cancer Science|2021Cited by 18
Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non‐small<scp>‐</scp>cell lung cancer in KEYNOTE‐407Shunichi Sugawara, Terufumi Kato, Kentaro Tanaka et al.|Cancer Science|2023Cited by 16